283 related articles for article (PubMed ID: 38339290)
1. Optimizing Clinical Implementation of Hypofractionation: Comprehensive Evidence Synthesis and Practical Guidelines for Low- and Middle-Income Settings.
Starling MTM; Thibodeau S; de Sousa CFPM; Restini FCF; Viani GA; Gouveia AG; Mendez LC; Marta GN; Moraes FY
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339290
[TBL] [Abstract][Full Text] [Related]
2. Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa.
Swanson W; Samba RN; Lavelle M; Elzawawy A; Sajo E; Ngwa W; Incrocci L
Front Oncol; 2021; 11():725103. PubMed ID: 34926247
[TBL] [Abstract][Full Text] [Related]
3. Practical considerations for prostate hypofractionation in the developing world.
Yan M; Gouveia AG; Cury FL; Moideen N; Bratti VF; Patrocinio H; Berlin A; Mendez LC; Moraes FY
Nat Rev Urol; 2021 Nov; 18(11):669-685. PubMed ID: 34389825
[TBL] [Abstract][Full Text] [Related]
4. Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy.
Irabor OC; Swanson W; Shaukat F; Wirtz J; Mallum AA; Ngoma T; Elzawawy A; Nguyen P; Incrocci L; Ngwa W
JCO Glob Oncol; 2020 Apr; 6():667-678. PubMed ID: 32343628
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated Radiotherapy in African Cancer Centers.
Swanson W; Kamwa F; Samba R; Ige T; Lasebikan N; Mallum A; Ngoma T; Sajo E; Elzawawy A; Incrocci L; Ngwa W
Front Oncol; 2020; 10():618641. PubMed ID: 33680940
[TBL] [Abstract][Full Text] [Related]
6. Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients.
Nicosia L; Mazzola R; Rigo M; Figlia V; Giaj-Levra N; Napoli G; Ricchetti F; Corradini S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2547-2554. PubMed ID: 31324979
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD; Clark MA; Henke LE; Kishan AU; Portelance L; Parikh PJ; Bassetti MF; Nagar H; Rosenberg SA; Mehta MP; Refaat T; Rineer JM; Smith A; Seung S; Zaki BI; Fuss M; Mak RH
Clin Transl Radiat Oncol; 2023 Jan; 38():161-168. PubMed ID: 36466748
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
Foerster R; Zwahlen DR; Buchali A; Tang H; Schroeder C; Windisch P; Vu E; Akbaba S; Bostel T; Sprave T; Zamboglou C; Zilli T; Stelmes JJ; Telkhade T; Murthy V
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673077
[TBL] [Abstract][Full Text] [Related]
10. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionation as a solution to radiotherapy access in latin america: expert perspective.
Santos M; Chavez-Nogueda J; Galvis JC; Merino T; Oliveira E Silva L; Rico M; Sarria G; Sisamon I; Garay O
Rep Pract Oncol Radiother; 2022; 27(6):1094-1105. PubMed ID: 36632306
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
13. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionation and Stereotactic Body Radiation Therapy in Inoperable Locally Advanced Non-small Cell Lung Cancer.
Rico M; Martínez M; Rodríguez M; Rosas L; Barco A; Martínez E
J Clin Transl Res; 2021 Apr; 7(2):199-208. PubMed ID: 34104822
[TBL] [Abstract][Full Text] [Related]
15. MO-F-BRCD-02: SBRT (Part 2): Physics and Quality Assurance Updates.
Perks J; Benedict S
Med Phys; 2012 Jun; 39(6Part21):3873. PubMed ID: 28518227
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiation therapy for breast cancer in the elderly.
Jardel P; Kammerer E; Villeneuve H; Thariat J
Transl Cancer Res; 2020 Jan; 9(Suppl 1):S86-S96. PubMed ID: 35117950
[TBL] [Abstract][Full Text] [Related]
17. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
